Skip to content

Merit Medical Systems

US · MMSI #2114 by market cap Listed 1970
84.34 -0.07 -0.08%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Fair Value how this is computed

Near fair value
79.97 fair value ≈ 108.21 136.44
  • Implied fair-value range of 79.97-136.44, from this stock's own trailing 5-year average P/E applied to trailing EPS.
  • Current price is -22.1% below the average-multiple fair value of 108.21.

Valuation each multiple against its own 5-year range

P/B ratio 2.98 Cheap vs history 12th percentile
5-year average 3.53 · #28 of 51 in Medical Instruments & Supplies
P/E ratio 32.45 Cheap vs history 7th percentile
5-year average 50.80 · forward 27.88 · #16 of 27 in Medical Instruments & Supplies
P/S ratio 3.22 Cheap vs history 24th percentile
5-year average 3.53 · forward 3.03 · #32 of 51 in Medical Instruments & Supplies

Vs. peers Medical Instruments & Supplies

Company Market cap P/E (TTM) P/B Div yield
Merit Medical Systems (MMSI) 5.05B 31.59 2.90 0.00%
Intuitive Surgical (ISRG) 138.33B 48.25 8.65 0.00%
Becton Dickinson & Co (BDX) 57.96B 52.02 2.35 1.97%
Alcon (ALC) 35.92B 54.24 1.64 0.48%
ResMed (RMD) 33.14B 21.46 5.57 1.04%
Medline (MDLN) 32.55B 57.52 2.76 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value89.52 Economic moatNarrow UncertaintyMedium

Trading 6.1% below Morningstar's fair value estimate.

Fair value

Merit Medical Systems Inc receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 3% discount to our quantitative fair value estimate of $89.52 per share; however, some caution is warranted due to this estimate's medium uncertainty rating.

The firm's profitability strengthens our valuation estimate. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. For example, the firm's free cash flow to assets ratio of 0.1 falls in the top 40% compared with peers globally. Relative to its asset base, the company is generating a compelling amount of free cash flow, which contributes to our view that shares are undervalued.

Conversely, the company's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 33.4%, a core component of valuation, ranks in the bottom 30% compared with global peers. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

Economic moat

The company's narrow quantitative moat rating indicates it could outearn its cost of capital and maintain robust margins for 10 years or longer. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Merit Medical Systems discussion 0 comments

Add a comment